Genmab Wins European Commission Approval for TEPKINLY® Combination Genmab A/S has announced that the European Commission (EC) has granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab…
Orion and Shilpa Medicare Expand European Nivolumab Biosimilar Partnership Shilpa Medicare Limited has announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and long-term…
Incyte Completes $1.25 Billion Acquisition of Vega Therapeutics, Expanding Hematology Portfolio with Late-Stage von Willebrand Disease Therapy VGA039 Incyte has announced the successful completion of its acquisition of Vega Therapeutics,…
PharmaEssentia Receives Health Canada Approval for BESREMi® to Treat Adults with Polycythemia Vera PharmaEssentia Corporation, a Taiwan-based global biopharmaceutical company specializing in the development of innovative biologic therapies for hematology…
Agenus Reports Landmark Three-Year Phase 1b Data Showing Durable Survival with Botensilimab Plus Balstilimab in Refractory MSS Metastatic Colorectal Cancer Agenus Inc., a biotechnology company focused on advancing next-generation immuno-oncology…
Elucid to Showcase Next-Generation AI-Powered Coronary CT Technologies and Advance Its CCTA 3.0 Vision at SCCT 2026 Elucid, a medical technology company specializing in artificial intelligence-powered coronary CT angiography (CCTA)…
Ionis Pharmaceuticals Completes Enrollment in Pivotal Phase 3 REVEAL Study Cohort Evaluating Obudanersen for Angelman Syndrome Ionis Pharmaceuticals, Inc. has announced the completion of enrollment in the pivotal pediatric cohort…
Alzheon to Present Nine Scientific Posters at AAIC 2026 Highlighting New Clinical, Imaging, Biomarker, and Long-Term Data for Investigational Alzheimer’s Therapy Valiltramiprosate Alzheon, Inc., a clinical-stage biopharmaceutical company focused on…
Signatera™ MRD Test Predicts Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer Natera, Inc., a global leader in cell-free DNA testing and precision medicine, has announced the publication…
Novartis Secures EU Approval for Itvisma® in SMA Novartis has announced that the European Commission (EC) has granted approval for Itvisma® (onasemnogene abeparvovec) for the treatment of children aged two…
Immunomic Therapeutics Doses First Participant in Phase 1 Trial of ITI-9001 Therapeutic Vaccine for Japanese Cedar Pollen Allergy Immunomic Therapeutics Inc. (ITI), a clinical-stage biotechnology company and subsidiary of HLB,…
Visby Medical Receives FDA Clearance for First At-Home Multi-Viral PCR Test for COVID-19 and Influenza Visby Medical, a company focused on developing rapid molecular diagnostics for use at home, has…
